Serum soluble mediators and inflammatory cytokines may drive cardiomyoblast injury in COVID-19 mRNA vaccine-induced myocarditis, suggesting a potential role for targeted anti-inflammatory therapies.
Answers are grounded in this paper and cite their sources.
No immediate change to myocarditis management; leaves open cytokine-targeted therapy validation in prospective studies.
Our results opened the possibility of the inflammatory cytokines or serum soluble mediators as key factors for vaccine-associated myocarditis. In this regard, identifying anti-inflammatory molecules that reduce inflammatory cytokines could help avoid vaccine-induced myocardial inflammation.
No takes yet. Share an insight, caveat, or question.
Paredes-Vázquez et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: